AZ194
Modify Date: 2024-01-12 13:24:51
AZ194 structure
|
Common Name | AZ194 | ||
|---|---|---|---|---|
| CAS Number | 2241651-99-8 | Molecular Weight | 567.62 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C34H31F2N3O3 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of AZ194AZ194 is a first-in-class, orally active inhibitor of CRMP2-Ubc9 interaction and inhibitor of NaV1.7 (IC50=1.2 μM). AZ194 blocks SUMOylation of CRMP2 to selectively reduce the amount of surface-expressed NaV1.7. Antinociceptive effects[1]. |
| Name | CRMP2-Ubc9-NaV1.7 inhibitor 194 |
|---|
| Description | AZ194 is a first-in-class, orally active inhibitor of CRMP2-Ubc9 interaction and inhibitor of NaV1.7 (IC50=1.2 μM). AZ194 blocks SUMOylation of CRMP2 to selectively reduce the amount of surface-expressed NaV1.7. Antinociceptive effects[1]. |
|---|---|
| Related Catalog | |
| In Vivo | AZ194 would provide pain relief in rat models of chemotherapy- and nerve injury- induced neuropathic pain. AZ194 (orally; at 2 and 10 mg/kg) restores mechanical sensitivity in animals with chemotherapy-induced and nerve injury-induced neuropathic nociception[1]. AZ194 (10 mg/kg; ip; CD1 male mice) does not affect motor performance (open field). AZ194 synergizes with commonly used painkillers, engages NaV1.7-dependent endogenous opioid signaling[1]. |
| References |
| Molecular Formula | C34H31F2N3O3 |
|---|---|
| Molecular Weight | 567.62 |